Repository logo
 

SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion.

Accepted version
Peer-reviewed

Type

Article

Change log

Authors

Ferreira, Isabella ATM 
Kemp, Steven A 
Datir, Rawlings 
Saito, Akatsuki 
Meng, Bo 

Abstract

The SARS-CoV-2 B.1.617 variant emerged in the Indian state of Maharashtra in late 2020. There have been fears that 2 key mutations seen in the receptor-binding domain, L452R and E484Q, would have additive effects on evasion of neutralizing antibodies. We report that spike bearing L452R and E484Q confers modestly reduced sensitivity to BNT162b2 mRNA vaccine-elicited antibodies following either first or second dose. The effect is similar in magnitude to the loss of sensitivity conferred by L452R or E484Q alone. These data demonstrate reduced sensitivity to vaccine-elicited neutralizing antibodies by L452R and E484Q but lack of synergistic loss of sensitivity.

Description

Keywords

B.1.617, COVID-19, Indian variant, SARS-CoV-2, antibody escape, evasion, fitness, infectivity, neutralizing antibodies, resistance, spike mutation, Angiotensin-Converting Enzyme 2, Animals, Antibodies, Neutralizing, Antibodies, Viral, BNT162 Vaccine, COVID-19, COVID-19 Vaccines, Chlorocebus aethiops, HEK293 Cells, Humans, Immune Evasion, India, Mutation, Protein Binding, SARS-CoV-2, Serine Endopeptidases, Spike Glycoprotein, Coronavirus, Vero Cells

Journal Title

J Infect Dis

Conference Name

Journal ISSN

0022-1899
1537-6613

Volume Title

224

Publisher

Oxford University Press (OUP)

Rights

All rights reserved
Sponsorship
Wellcome Trust (108082/A/15/Z)
Rosetrees Trust (M957)
Addenbrooke's Charitable Trust (ACT) (900296)